Acutaas Chemicals logo

Acutaas Chemicals

ACUTAAS NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹27,934 Cr
Volatility
Moderate
P/E Ratio
71.73
EBITDA
₹522 Cr
Return on Equity
20.83%
Debt to Equity
0.02
Book Value
₹201.97
EPS
₹15.13
52W High
₹3,740
52W Low
₹1,302

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 45.8% CAGR over last 5 years

Weaknesses

2
  • Stock is trading at 16.8 times its book value
  • Promoter holding has decreased over last 3 years: -6.75%

Growth Rate

Revenue Growth
34.89% higher than 3Y
Net Income Growth
122% higher than 3Y
Cash Flow Change
147% higher than 3Y
ROE
71.44% higher than 3Y
ROCE
67.9% lower than 3Y
EBITDA Margin (Avg.)
55.43% lower than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 2d ago
AI opinion · based on fundamentals
Risk high

Acutaas Chemicals Ltd is a small-cap healthcare/chemicals company with a market cap of ₹27,934 Cr, trading at a PE of 72.9x and 17.1x book value. The company has delivered strong profit growth of 104% TTM and 62% CAGR over 3 years while remaining almost debt-free, but the stock's 134% one-year price surge has pushed valuations to elevated levels.

Bull Case 7
  • Company is almost debt-free, providing financial flexibility and low interest burden in a capital-intensive chemicals sector
  • TTM profit growth of 104% signals a sharp acceleration in earnings compared to the 5-year CAGR of 46%
  • Compounded sales growth of 30% over 3 years and 32% over 5 years demonstrates consistent top-line expansion
  • ROE has improved from an 18% 5-year average to 24% in the last year, indicating improving capital efficiency
  • Compounded profit growth of 62% over 3 years significantly outpaces the 30% sales CAGR, reflecting expanding margins
  • 5-year compounded profit CAGR of 45.8% shows sustained earnings momentum beyond a single strong year
  • TTM sales growth of 41% suggests the business continues to scale at a healthy pace in the most recent period
Bear Case 8
  • PE ratio of 72.9x is significantly elevated, pricing in substantial future growth and leaving little margin for execution misses
  • Stock trades at 17.1x book value, well above typical chemical or healthcare peers, suggesting rich valuation on an asset basis
  • Promoter holding has declined by 6.75% over the last 3 years, which may signal reduced insider confidence or dilution
  • Stock price has surged 134% in 1 year, raising the risk of mean reversion or correction if growth disappoints
  • Dividend yield of just 0.07% offers negligible income return, meaning investors are entirely dependent on capital appreciation
  • Key profitability metrics like ROCE and debt-to-equity are unavailable, limiting visibility into operational efficiency and balance sheet health
  • 10-year sales and profit CAGR data is unavailable, making it difficult to assess the company's long-term track record and consistency
  • Small market cap of ₹27,934 Cr combined with rapid price appreciation can lead to higher volatility and lower liquidity during corrections

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 2h ago
Positives 4
  • FY26 PAT surges 122% YoY Aug 29

    Consolidated revenue hit ₹13,394 Mn (up 33% YoY) with PAT jumping 122% to ₹3,564 Mn and EBITDA margin expanding to 35.9%.

  • Korea semiconductor plant inaugurated Aug 28

    Subsidiary Indichem inaugurated a semiconductor materials plant in South Korea, built in 11 months, enabling a two-country synthesis-and-refining model between India and Korea.

  • ₹212 crore capex approved Aug 22

    Board approved ₹212 crore capital expenditure for electronic grade chemicals manufacturing in Gujarat.

  • Process patent win, 11 total Sep 10

    Secured a patent for 2,4-dimethylthiophenol preparation, bringing total patent count to 11 and reinforcing R&D capabilities.

Neutral 3
  • HPAPI pilot plant in Surat Sep 4

    Inaugurated an OEB 4 containment pilot plant at Sachin, Surat on Sep 4 for R&D on high-potency API intermediates targeting oncology therapies.

  • ₹119 Cr ECMS govt incentive Aug 18

    Received MeitY approval for ₹119.12 crore incentive under ECMS. This is a subsidy benefit with no immediate revenue impact or disclosed order book.

  • FY26 BRSR report filed Aug 29

    Submitted Business Responsibility and Sustainability Report for FY26 with ESG metrics and third-party assurance by TÜV SÜD.

TL;DR: Acutaas Chemicals is firing on multiple cylinders — FY26 financials are strong with 122% PAT growth and 35.9% EBITDA margins, while capex into electronic chemicals and a new Korea plant signal aggressive diversification beyond pharma intermediates. No visible headwinds in recent news, though the stock's expanding ambitions across semiconductors, HPAPIs, and electronic chemicals will need execution discipline. The trend is clearly improving with earnings momentum and capacity buildout pointing to continued growth.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
154
172
166
225
177
247
275
308
207
306
393
433
330
Expenses
120
148
140
182
147
198
206
224
156
211
243
249
217
Operating Profit
34
25
27
43
30
49
69
85
51
95
151
184
113
OPM %
22%
14%
16%
19%
17%
20%
25%
28%
25%
31%
38%
42%
34%
Other Income
1
-30
3
1
1
8
2
6
16
10
5
11
2
Interest
1
1
3
2
4
0
1
1
1
1
1
1
1
Depreciation
4
4
4
5
6
7
6
7
8
8
10
10
10
PBT
31
-10
24
37
20
50
63
83
58
96
145
184
104
Tax %
28%
71%
25%
31%
26%
25%
28%
24%
24%
25%
27%
27%
28%
Net Profit
22
-17
18
26
15
38
45
63
44
72
106
134
75
EPS in Rs
2.71
-2.55
2.27
3.41
1.71
4.56
5.49
7.63
5.41
8.82
13.19
16.09
9.07
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
160
188
239
240
341
520
617
717
1,007
1,339
1,462
Expenses
137
157
196
198
260
415
493
589
775
859
919
Operating Profit
23
31
42
42
80
105
123
128
232
480
543
OPM %
14%
16%
18%
17%
24%
20%
20%
18%
23%
36%
37%
Other Income
0
3
0
2
1
3
4
-25
17
42
27
Interest
3
3
5
6
6
6
2
6
6
3
4
Depreciation
1
2
3
4
4
10
12
16
27
36
38
PBT
19
28
35
35
72
91
112
82
216
483
529
Tax %
35%
35%
34%
21%
25%
21%
26%
41%
26%
26%
—
Net Profit
12
18
23
27
54
72
83
49
160
356
387
EPS in Rs
40.17
61.67
11.1
13.08
8.57
9.87
11.43
5.8
19.38
43.51
47.17
Div. Payout %
0%
0%
0%
0%
0%
15%
13%
26%
8%
6%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
2
2
10
10
32
36
36
37
41
41
Reserves
37
56
72
101
135
486
558
637
1,269
1,613
Borrowings
27
44
54
59
137
1
4
217
13
36
Other Liabilities
43
54
77
61
110
136
169
205
227
295
Total Liabilities
109
155
213
232
413
659
767
1,096
1,549
1,984
Fixed Assets
28
32
79
85
186
205
259
427
570
745
CWIP
11
30
2
12
0
3
30
125
130
332
Investments
1
3
2
2
1
2
2
0
0
0
Other Assets
68
91
131
133
225
450
477
543
848
907
Total Assets
109
155
213
232
413
659
767
1,096
1,549
1,984
Figures in ₹ Crores

Cash Flow

Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
29
8
15
27
28
-12
66
125
118
292
Investing
-19
-25
-21
-24
-101
-121
-33
-365
-224
-266
Financing
-7
15
6
0
72
140
-12
239
261
4
Net Cash Flow
3
-2
0
3
-1
8
20
-1
156
30
Free Cash Flow
10
-16
-7
6
-77
-46
-31
-155
-76
-36
CFO/OP
153
53
68
85
52
10
73
116
71
84
Figures in ₹ Crores

Ratios

Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
83
97
116
86
129
115
136
105
105
99
Inventory Days
76
89
95
148
123
150
131
139
119
149
Days Payable
148
154
168
146
172
158
157
119
103
99
Cash Conversion Cycle
11
31
43
88
80
107
111
125
121
149
Working Capital Days
46
64
28
34
51
141
139
80
123
116
ROCE %
—
38%
34%
27%
33%
24%
21%
16%
20%
32%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Acutaas Chemicals insights

69 extracted metrics + investor summaries across FY14–FY27.

Log in — free

Shareholding Pattern

Govt.0.01%Promot.32.66%Public21.72%Others4.44%DIIs19.56%FIIs21.61%As ofJun 2026

Documents

Frequently Asked Questions about Acutaas Chemicals

What does Acutaas Chemicals Ltd do?
Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals...
Where is Acutaas Chemicals Ltd (ACUTAAS) listed?
Acutaas Chemicals Ltd trades as ACUTAAS on the NSE and under code 543349 on the BSE.
Which sector does Acutaas Chemicals Ltd belong to?
Acutaas Chemicals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Acutaas Chemicals Ltd?
Acutaas Chemicals Ltd has a market capitalisation of ₹27,934 Cr, which places it in the Large Cap band.
What is the PE ratio of Acutaas Chemicals Ltd?
Acutaas Chemicals Ltd trades at a PE ratio of 71.73, on earnings per share of ₹15.13, against a book value of ₹201.97 per share.
What is the 52-week high and low of Acutaas Chemicals Ltd?
Over the last 52 weeks Acutaas Chemicals Ltd has traded between ₹1,302 and ₹3,740.
Does Acutaas Chemicals Ltd pay dividends?
Acutaas Chemicals Ltd has a dividend yield of 0.07%.
What is the Return on Equity (ROE) of Acutaas Chemicals Ltd?
Acutaas Chemicals Ltd reported a return on equity of 20.83%. Its debt-to-equity ratio is 0.02.

Company Information

Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals.[1]

Website amiorganics.com
CEO Mr. Nareshkumar Ramjibhai Patel
Employees 879
Listed 2021-09-14
Face Value ₹ 5
Issued Size 8,18,71,122

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ACUTAAS.md for Acutaas Chemicals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List